Updated:
Biodexa Pharmaceuticals
Stephen Stamp's Biodexa Pharmaceuticals acquires late-stage cancer assets and pushes them toward clinical catalysts.
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals emerged from the 2019 reverse merger of Midatech Pharma into a NASDAQ-listed shell, establishing a Cardiff-headquartered clinical-stage company focused on rare and orphan oncology indications. CEO Stephen Stamp and CMO Dr. Gary Acton run a small team that hunts for de-risked, late-stage assets shelved by larger pharmaceutical companies. The firm's lead programs include MTX110, a formulation of panobinostat delivered via convection-enhanced delivery for diffuse midline glioma and glioblastoma multiforme — two brain cancers with no approved therapies. The company's strategy relies on reformulating existing drugs using proprietary delivery platforms: Q-Sphera 3D printing for sustained release and MidaSolve nano-inclusion for solubilizing insoluble compounds. Biodexa does not originate targets; it in-licenses Phase II-ready candidates, conducts focused clinical trials, and aims to reach value-inflection points where partners or acquisition become viable. Its pipeline also carries MTD211, a reformulated brexpiprazole for autism-related irritability, and MTX325, a second-generation pan-HDAC inhibitor. Trial sites have spanned the United States and Europe, reflecting a transatlantic regulatory approach. Biodexa trades on the NASDAQ under the ticker BDRX, with its ordinary shares also cross-listed on the London Stock Exchange's AIM market. The firm maintains its registered office in Cardiff, Wales, while operating a small US footprint driven by clinical trial coordination and investor relations needs. Its market capitalization, rather than AUM, defines financial scale — raising capital through public markets, including a 2024 financing round intended to extend the cash runway through Phase II data readouts for its brain cancer programs (per public filings, 2024). The company has used the RD8200 vehicle and similar corporate structures for tax-efficient R&D incentives in the United Kingdom. Biodexa's structural differentiator is its inverse biotech model: instead of building a discovery engine, it functions as a publicly traded asset aggregator for niche oncology programs. This positions it closer to a specialty finance vehicle for clinical assets — deploying public equity into single-product company strategies where binary clinical data releases drive revaluation. The firm's governance is conventional, with a board chaired by a non-executive director and key man risk concentrated in a small executive team.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
Cardiff
Corporate office
Cardiff, Wales, United Kingdom
Principals
Stephen Stamp
Chief Executive Officer
Dr. Gary Acton
Chief Medical Officer
Sector focus
Frequently asked questions
What is Biodexa's business model?
Biodexa in-licenses deprioritized clinical-stage drug candidates — typically from larger pharmaceutical companies — and advances them through focused trials to generate value-inflection data. It does not operate a traditional drug-discovery platform. The firm uses public equity financing to fund these programs, aiming for partnership or acquisition exits upon positive readouts. Its proprietary delivery technologies, Q-Sphera and MidaSolve, are used to reformulate existing compounds for niche oncology and CNS indications.
Which cancers does Biodexa target?
The company concentrates on rare and orphan brain cancers with no approved therapies. Its lead candidate, MTX110, is in development for diffuse midline glioma and recurrent glioblastoma multiforme. These tumors are uniformly fatal in pediatric and adult populations, creating a high-unmet-need, orphan-drug positioning that potentially qualifies for accelerated regulatory pathways in the US and Europe.
How is Biodexa financed?
Biodexa is a publicly traded company listed on NASDAQ (BDRX) and cross-listed on the London Stock Exchange's AIM market. It raises capital through equity offerings and at-the-market programs rather than managing third-party funds. The company's financial scale is measured by market capitalization, not assets under management, and it has periodically tapped US and UK investors to fund clinical trials, including a 2024 capital raise to extend its cash runway.
What drug delivery technologies does Biodexa own?
Biodexa controls two proprietary formulation platforms designed to improve existing drugs. Q-Sphera uses 3D printing to create sustained-release microspheres for injectable compounds. MidaSolve uses a nano-inclusion technology to solubilize drugs that are otherwise difficult to formulate. Both platforms allow Biodexa to take known active ingredients from other companies and create patentable, reformulated versions for new cancer or CNS indications.
Who makes investment decisions at Biodexa?
Investment and strategic decisions are made by a small executive team led by CEO Stephen Stamp. The board of directors, chaired by a non-executive, provides governance oversight. Because the company operates as a single-product-clinic entity with a lean headcount, the CEO and CMO effectively drive asset selection, clinical strategy, and capital allocation decisions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: